Noxopharm Preclinical Data Further Supports Anti-Inflammatory Role of Idronoxil in the Treatment of COVID-19
Australian clinical-stage drug development company Noxopharm (ASX:NOX) has reported preclinical data that further supports the role of experimental anti-cancer drug, idronoxil, the active ingredient in Veyonda® , as an anti-inflammatory drug for early-stage COVID-19 treatments. A recent preclinical trial, conducted in partnership with Australia’s Hudson Institute of Medical Research (Hudson Institute), has identified that idronoxil inhibits the enzyme, TANK-binding kinase 1 (TBK1), an action that potentially dampens the inflammatory response causing the progression of COVID-19 disease from mild-to-severe, but not compromising the body’s ability to fight the virus.
These preclinical findings support preliminary top-line positive results the company shared earlier from its NOXCOVID Phase I clinical trial , which tested the suitability of idronoxil (Veyonda) as an effective anti-inflammatory in patients hospitalized with moderate COVID-19 disease. One particular relevance of TBK1 as a drug target is its role in responding to infections from RNA viruses including the respiratory RNA viruses - coronaviruses, influenza virus and respiratory syncytial virus.
Associate Professor Michael Gantier , Head of the Nucleic Acids and Innate Immunity Laboratory at Hudson Institute said: “TBK1 is a point of convergence of many inflammatory pathways, and a target under significant investigation by several big pharmaceutical companies. Our latest findings, which are being prepared for publication, demonstrate that idronoxil may have applications in a range of diseases where TBK1 facilitates aberrant inflammation. Critically, TBK1 also directly controls production of interferon-beta, a cytokine associated with long-COVID symptoms. This suggests that idronoxil may not only be useful to prevent progression of COVID-19 patients from mild to severe disease, but also may decrease the risk of long-lasting post-infectious symptoms, seen in up to half of COVID-19 patients.”
Noxopharm Limited (ASX:NOX) is an Australian clinical-stage drug development company focused on the treatment of cancer and cytokine storm (septic shock).
Veyonda® is the Company’s first pipe-line drug candidate currently in Phase 2 clinical trialling. Veyonda® has two main drug actions — a moderating effect on the ceramide/sphingosine-1-phosphate balance and inhibition of STING signalling. Activity against the former target contributes to its dual-acting oncotoxic and immunomodulatory functions designed to enhance the effectiveness and safety of standard oncology treatments, i.e., chemotherapies, radiation therapies, and immune checkpoint inhibitors. Activity against the latter target provides an anti-inflammatory effect, as well as contributing to an anti-cancer action, but also potentially blocking septic shock.
Noxopharm is running comprehensive drug discovery programs in both oncology and inflammation, and is the major shareholder of U.S. biotechnology company, Nyrada Inc (ASX:NYR), which is active in the areas of drug development for cardiovascular and neurological diseases.
About Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
PANASONIC-CORPORATION17.9.2021 09:02:13 CEST | Press release
Panasonic Completes Acquisition of Blue Yonder
NY-IFF16.9.2021 22:17:12 CEST | Press release
IFF Appoints Glenn Richter as Executive Vice President and Chief Financial Officer
NAGA-GROUP16.9.2021 22:02:11 CEST | Press release
The NAGA Group AG: Christian Angermayer's Apeiron Investment Group and Fosun Join Forces to Further Drive NAGA Growth
CA-LANDMARK-WORLDWIDE16.9.2021 20:02:03 CEST | Press release
Landmark Celebrates 30 Years as the Industry Leader in Personal & Professional Growth, Training and Development
IL-ISACA16.9.2021 19:23:08 CEST | Press release
ISACA to Host Inaugural ISACA Conference Europe Virtual Event
PA-VIRPAX-PHARMA16.9.2021 19:02:07 CEST | Press release
Virpax® Pharmaceuticals Announces Closing of $40 Million Public Offering of Common Stock
CA-VERIMATRIX16.9.2021 17:47:13 CEST | Press release
Verimatrix To Highlight Success In Enabling Secure Virtual Hollywood Events at Variety Entertainment & Technology Summit
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom